Throughout his career, Dr. Sorensen has been also been active in fostering public-private collaborations for clinical cancer research including the National Cancer Institute, C-Change, Friends of Cancer Research and other organizations. He is a frequent speaker and panel participant on optimizing cancer R&D, including presentations at the Woodrow Wilson Center in Washington, DC, the 2004 Bioethical Symposium in Tampa, FL, the 2005 Tokyo Pharma Partnering Conference &, the 2005 Shanghai Bio-Forum conference, the 2005 Milken Institute Global Conference ("Biopharmaceuticals: The Innovation Pipeline Race"), BIO 2006 ("Early-Stage Business Models in Cancer"), the 2007 R&D Leaders' Forum ("Biotech R&D Across Borders: The Ascenta Experience") Philadelphia, PA, and the 2007 China R&D Summit ("Making Innovative Medicines Faster and Cost-Efficiently"), Shanghai, CN.
"We are extremely pleased that Dr. Sorensen has joined the Lixte Biotechnology board of directors. Mel is internationally recognized for his expertise in clinical oncology and in meeting the challenges of cancer drug development. In addition to his depth of knowledge and experience in applied cancer research, he has demonstrated remarkable administrative skills in bringing together the expertise of the diverse groups needed for the effective and safe development of important new anti-cancer drugs. We very much look forward to working with him," stated Dr. Kovach.
About Lixte Biotechnology Holdings, Inc.:
Lixte is a biotechnology company engaged in development of improved
treatments for cancer and improved methods for detecting cancer. As such,
Lixte is both a c
|SOURCE Lixte Biotechnology Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved